Recent performance context for Stryker (SYK)

Stryker (SYK) has seen its stock retreat recently, with the price down about 2% over the past day and 6% over the past week, contributing to a decline of roughly 23% over the past 3 months.

Over a longer horizon, the stock is also down about 16% year to date and 22% over the past year, while its 3 year and 5 year total returns remain positive. This mix of shorter term weakness and longer term gains is the backdrop for assessing today’s valuation and fundamentals.

The recent slide in Stryker’s share price, with the stock down over the past week and quarter despite a higher level over the past 3 and 5 years on a total shareholder return basis, suggests momentum has faded as investors reassess growth prospects and risks around its medical technology portfolio and broader market sentiment.

If you are considering how this shift in momentum compares with other healthcare-related opportunities, it can be useful to scan the wider space of medical technology and digital health by reviewing 39 healthcare AI stocks

With Stryker’s share price under pressure despite positive multi year total returns and analyst targets sitting higher than today’s level, is the recent pullback offering you value, or is the stock already pricing in future growth?

Most Popular Narrative: 24.6% Undervalued

At a last close of $293.30 versus a narrative fair value of $389.24, Stryker is framed as meaningfully discounted, with that gap tied directly to long term earnings and cash flow assumptions.

The ongoing industry shift to outpatient and minimally invasive procedures, where Stryker is a leading supplier of ASC infrastructure and advanced surgical solutions, positions the company to benefit from increased procedure volumes and deeper customer penetration, bolstering both revenue and operating leverage.

Curious what has to happen for that higher value to hold up? The narrative leans on steady revenue gains, rising margins and a rich future earnings multiple. The exact mix of those assumptions is where the story gets interesting.

Result: Fair Value of $389.24 (UNDERVALUED)

However, prolonged regulatory delays and the recent cyberattack, along with associated system outages and surgery disruptions, could challenge the earnings and valuation assumptions behind that 24.6% discount.

Another View: What Earnings Multiples Are Saying

That 24.6% discount to the $389.24 fair value is based on long term earnings and cash flow assumptions, but the current P/E of 33.7x tells a different story. It sits above the estimated fair ratio of 30.7x, the peer average of 28.1x, and the US Medical Equipment industry at 24.2x.

In practice, that means the stock already carries a richer earnings tag than both peers and the fair ratio that the market could move toward. As a result, any slip in execution or sentiment could compress the multiple quickly. The question is whether the growth and quality on offer justify paying that premium.

Next Steps

With mixed signals on valuation, growth potential, risks and rewards, it makes sense to move quickly, review the key numbers yourself and weigh both sides using 4 key rewards and 2 important warning signs

Looking for more investment ideas?

If Stryker is already on your radar, do not stop there. Use focused stock lists to spot fresh opportunities before they are crowded and potential upside narrows.

• Scan for quality at a discount by hunting through 46 high quality undervalued stocks that pair solid fundamentals with prices below their estimated worth.
• Prioritise strength and resilience with the solid balance sheet and fundamentals stocks screener (47 results) to find companies that keep debt in check and liquidity robust.
• Get ahead of the crowd by searching the screener containing 22 high quality undiscovered gems that combine strong numbers with relatively low investor attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.